Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZS NASDAQ:AKTX NASDAQ:CPIX NASDAQ:RGLS NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.08+1.3%$3.24$3.96▼$12.00$5.52M1.557,305 shs3,223 shsAKTXAkari Therapeutics$0.77+2.8%$0.88$0.57▼$3.15$25.24M0.3683,204 shs1,114 shsCPIXCumberland Pharmaceuticals$3.58-1.6%$3.32$1.04▼$7.25$53.56M-0.41528,151 shs5,978 shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/ASNGXSoligenix$1.63-1.5%$2.41$1.09▼$6.23$6.97M1.953.86 million shs34,871 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris0.00%0.00%0.00%-26.49%-16.76%AKTXAkari Therapeutics-2.26%-23.20%-7.36%-33.69%-65.16%CPIXCumberland Pharmaceuticals+2.25%+7.69%+15.56%+2.25%+198.36%RGLSRegulus Therapeutics0.00%0.00%0.00%0.00%+444.00%SNGXSoligenix-2.94%+1.23%-38.66%+16.20%-54.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.08+1.3%$3.24$3.96▼$12.00$5.52M1.557,305 shs3,223 shsAKTXAkari Therapeutics$0.77+2.8%$0.88$0.57▼$3.15$25.24M0.3683,204 shs1,114 shsCPIXCumberland Pharmaceuticals$3.58-1.6%$3.32$1.04▼$7.25$53.56M-0.41528,151 shs5,978 shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/ASNGXSoligenix$1.63-1.5%$2.41$1.09▼$6.23$6.97M1.953.86 million shs34,871 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris0.00%0.00%0.00%-26.49%-16.76%AKTXAkari Therapeutics-2.26%-23.20%-7.36%-33.69%-65.16%CPIXCumberland Pharmaceuticals+2.25%+7.69%+15.56%+2.25%+198.36%RGLSRegulus Therapeutics0.00%0.00%0.00%0.00%+444.00%SNGXSoligenix-2.94%+1.23%-38.66%+16.20%-54.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/AAKTXAkari Therapeutics 2.33Hold$3.30326.36% UpsideCPIXCumberland Pharmaceuticals 1.00SellN/AN/ARGLSRegulus Therapeutics 2.17Hold$8.807.84% UpsideSNGXSoligenix 2.00Hold$6.00269.23% UpsideCurrent Analyst Ratings BreakdownLatest AEZS, RGLS, CPIX, AKTX, and SNGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AKTXAkari TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CPIXCumberland PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SNGXSoligenixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025AKTXAkari TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CPIXCumberland PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SNGXSoligenixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/9/2025AKTXAkari TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.60(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.33N/AN/A$14.99 per share0.21AKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/ACPIXCumberland Pharmaceuticals$37.87M1.41$0.26 per share13.84$1.61 per share2.22RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/ASNGXSoligenix$120K58.09N/AN/A$1.64 per share0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%N/AAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-78.03%-31.62%11/18/2025 (Estimated)CPIXCumberland Pharmaceuticals-$6.48M-$0.22N/A∞N/A-6.97%7.48%2.66%11/6/2025 (Estimated)RGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%N/ASNGXSoligenix-$8.27M-$3.80N/AN/AN/AN/A-274.76%-129.20%11/14/2025 (Estimated)Latest AEZS, RGLS, CPIX, AKTX, and SNGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/18/2025Q3 2025AKTXAkari Therapeutics-$0.09N/AN/AN/AN/AN/A11/14/2025Q3 2025SNGXSoligenix-$0.63N/AN/AN/AN/AN/A8/14/2025Q2 2025SNGXSoligenix-$0.79-$0.82-$0.03-$0.82N/AN/A8/5/2025Q2 2025CPIXCumberland PharmaceuticalsN/A$0.02N/A-$0.05N/A$10.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/AAKTXAkari TherapeuticsN/AN/AN/AN/AN/ACPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93AKTXAkari TherapeuticsN/A0.190.19CPIXCumberland Pharmaceuticals0.191.301.17RGLSRegulus TherapeuticsN/A16.3116.31SNGXSoligenixN/A1.471.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%AKTXAkari Therapeutics5.06%CPIXCumberland Pharmaceuticals15.51%RGLSRegulus Therapeutics92.38%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%AKTXAkari Therapeutics38.10%CPIXCumberland Pharmaceuticals44.85%RGLSRegulus Therapeutics4.35%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataAKTXAkari Therapeutics932.62 million20.19 millionNot OptionableCPIXCumberland Pharmaceuticals8014.96 million8.25 millionOptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableSNGXSoligenix204.29 million4.16 millionNot OptionableAEZS, RGLS, CPIX, AKTX, and SNGX HeadlinesRecent News About These CompaniesSoligenix Updates United States Medical Advisory Board for Cutaneous T-Cell LymphomaOctober 14, 2025 | prnewswire.comSoligenix shares surge after safety milestone in Phase 3 CTCL trialOctober 7, 2025 | msn.comSoligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trialOctober 7, 2025 | msn.comSOLIGENIX, INC.: Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell LymphomaOctober 7, 2025 | finanznachrichten.deSOLIGENIX, INC.: Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell LymphomaOctober 7, 2025 | finanznachrichten.deSoligenix stock soars after DMC confirms safety in Phase 3 CTCL studyOctober 7, 2025 | investing.comSoligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaOctober 7, 2025 | prnewswire.comSoligenix (NASDAQ:SNGX) CEO Christopher Schaber Purchases 15,132 SharesOctober 4, 2025 | insidertrades.comSNGX: Public Offering Raises $7.5 Million; Expands European Medical Advisory BoardSeptember 30, 2025 | finance.yahoo.comSoligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell LymphomaSeptember 30, 2025 | prnewswire.comSoligenix Announces Closing of $7.5 Million Public OfferingSeptember 29, 2025 | prnewswire.comSoligenix stock tumbles after pricing $7.5 million public offeringSeptember 26, 2025 | za.investing.comSoligenix stock down after pricing $7.5M public offering to raise capitalSeptember 26, 2025 | msn.comSoligenix Announces Pricing of $7.5 Million Public OfferingSeptember 26, 2025 | prnewswire.comSoligenix Slumps Despite Word of New HireSeptember 24, 2025 | baystreet.caSoligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic AdvisorSeptember 23, 2025 | prnewswire.comSoligenix files to sell 2.91M shares of common stock, 2.91M warrantsSeptember 19, 2025 | msn.comSoligenix Tumbles After Company Publishes PaperSeptember 4, 2025 | baystreet.caSoligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related VirusesSeptember 4, 2025 | prnewswire.comSoligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEZS, RGLS, CPIX, AKTX, and SNGX Company DescriptionsAeterna Zentaris NASDAQ:AEZSAeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Akari Therapeutics NASDAQ:AKTX$0.77 +0.02 (+2.84%) As of 09:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Cumberland Pharmaceuticals NASDAQ:CPIX$3.58 -0.06 (-1.65%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Regulus Therapeutics NASDAQ:RGLSRegulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Soligenix NASDAQ:SNGX$1.62 -0.03 (-1.52%) As of 09:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
